Acetyl-L-Carnitine in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial

Please use this identifier to cite or link to this item:

Show simple item record

Files Size Format View
fac_ArnoldE_JChildAdolescPsychopharm_2007_17_6.pdf 239.4Kb PDF View/Open

dc.creator Arnold, L. Eugene
dc.creator Amato, Antonino
dc.creator Bozzolo, Hernan
dc.creator Hollway, Jill
dc.creator Cook, Amy
dc.creator Ramadan, Yaser
dc.creator Crowl, Lindsay
dc.creator Zhang, Dan
dc.creator Thompson, Susan
dc.creator Testa, Giussepe
dc.creator Kliewer, Vernon
dc.creator Wigal, Timothy
dc.creator McBurnett, Keith
dc.creator Manos, Michael 2012-03-19T19:38:40Z 2012-03-19T19:38:40Z 2007
dc.identifier.citation L. Eugene Arnold et al, "Acetyl-L-Carnitine in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial," Journal of Child and Adolescent Psychopharmacology 17, no. 6 (2007), doi:10.1089/cap.2007.018 en_US
dc.identifier.issn 1557-8992
dc.description.abstract Objective: To determine whether acetyl-L-carnitine (ALC), a metabolite necessary for energy metabolism and essential fatty acid anabolism, might help attention-deficit/hyperactivity disorder (ADHD). Trials in Down’s syndrome, migraine, and Alzheimer’s disease showed benefit for attention. A preliminary trial in ADHD using L-carnitine reported significant benefit. Method: A multi-site 16-week pilot study randomized 112 children (83 boys, 29 girls) age 5-12 with systematically diagnosed ADHD to placebo or ALC in weight-based doses from 500 to 1500 mg b.i.d. The 2001 revisions of the Conners’ parent and teacher scales (including DSM-IV ADHD symptoms) were administered at baseline, 8, 12, and 16 weeks. Analyses were ANOVA of change from baseline to 16 weeks with treatment, center, and treatment-by-center interaction as independent variables. Results: The primary intent-to-treat analysis, of 9 DSM-IV teacher-rated inattentive symptoms, was not significant. However, secondary analyses were interesting. There was significant (p = 0.02) moderation by subtype: superiority of ALC over placebo in the inattentive type, with an opposite tendency in combined type. There was also a geographic effect (p = 0.047). Side effects were negligible; electrocardiograms, lab work, and physical exam unremarkable. Conclusion: ALC appears safe, but with no effect on the overall ADHD population (especially combined type). It deserves further exploration for possible benefit specifically in the inattentive type. en_US
dc.language.iso en_US en_US
dc.publisher Mary Ann Liebert, Inc. Publishers en_US
dc.rights © 2007 Mary Ann Liebert, Inc. Publishers en_US
dc.title Acetyl-L-Carnitine in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial en_US
dc.type Article en_US
dc.identifier.doi 10.1089/cap.2007.018
dc.identifier.osuauthor arnold.6